AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00424619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D2
Description: 100 000 IU vitamin D2, one time bolus dose
Study NCT00424619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 1 time bolus dose
Study NCT02549859 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS) at 60 Hz
Description: Bilateral subthalamic nucleus deep brain stimulation at 60 Hz
Study NCT02549859 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS) at 130 Hz
Description: Bilateral subthalamic nucleus deep brain stimulation at 130 Hz
Study NCT02549859 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS) Off (Sham)
Description: Deep Brain Stimulation (DBS) Off (Sham)
Study NCT03616574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CA102N
Description: CA102N is a covalently bound conjugate of the biological polymer sodium hyaluronate (NaHA) and nimesulide (Nim).
Study NCT03616574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LONSURF
Description: LONSURF is a cytotoxic combination treatment of 2 new drugs: trifluridine, a thymidine-based nucleoside analog, and tipiracil, an inhibitor of thymidine phosphorylase.
Study NCT02790567 — intervention group
Intervention type: OTHER
Intervention: HEP score
Description: The HEP score is a clinicobiological score evaluating the probability of the HIT diagnosis.~The HEP score is based on the blood platelet count, the timing of the platelet decrease, the existence of clinical manifestations of HIT (thrombosis, haemorrhage, skin necrosis) and the existence of an other cause of thrombocytopenia.
Study NCT02790567 — intervention group
Intervention type: OTHER
Intervention: 4Ts score
Description: The 4Ts score is a clinicobiological score evaluating the probability of the HIT diagnosis. The 4Ts score is based on the change in blood platelet count during heparin therapy, the timing of platelet decrease, the existence of a thrombosis, and the existence of an other cause of thrombocytopenia.
Study NCT02790567 — intervention group
Intervention type: OTHER
Intervention: ID-PaGIA test
Description: The ID-PaGIA test is a particle gel immunoassay that detects immunoglobulins (Ig) G, A and M specific to the heparin/PF4 complexes.
Study NCT02790567 — intervention group
Intervention type: OTHER
Intervention: HIT-Ab(PF4-H) test
Description: The HIT-Ab(PF4-H) test consist in the incubation of plasma samples with latex beads coated PF4/polyvinylsulfate complexes. After binding of the plasma antibodies a monoclonal antibody recognizing PF4/heparin complexes is added. In the presence of human anti-PF4/heparin antibodies, binding of the monoclonal antibody and subsequent agglutination of latex beads is inhibited. Inhibition of agglutination is quantified and reported in arbitrary units (U/ml). A value equal or higher than 1.0 u/ml may indicate the presence of HIT antibodies.
Study NCT05082675 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HLA Matched allogeneic transplant
Study NCT05082675 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HLA Matched allogeneic transplant
Study NCT03207048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Daily left DLPFC, at 110% motor threshold, with a frequency of 10 Hz. Stimulation will be applied in 3-second trains with a 15-second inter-train interval, for 50 trains per session
Study NCT03207048 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation
Description: Sham Transcranial Magnetic Stimulation
Study NCT03240068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin 1-7
Description: This is a biologically active hormone of the renin-angiotensin system. It may play a beneficial role in regulation of blood pressure by dilating blood vessels and reducing inflammation.
Study NCT03240068 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Normal saline will be used as the placebo comparator.
Study NCT04399213 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 50 µg Histamine
Description: Skin prick through 50 µg/5 µL histamine diHCl
Study NCT04399213 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 15 µg Histamine
Description: Skin prick through 15 µg/5 µL histamine diHCl
Study NCT04399213 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 5 µg Histamine
Description: Skin prick through 5 µg/5 µL histamine diHCl
Study NCT04399213 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placebo (saline)
Description: Skin prick through 5 µL saline (0.9% NaCl)
Study NCT01710202 — intervention group
Intervention type: DRUG
Intervention: Hydrocortisone
Description: Each subject in this group will receive one 20mg hydrocortisone capsule to be taken by mouth.
Study NCT00497393 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Clinical Decision Unit
Description: a dedicated 2-bed area to see patients and then rotate them back into the waiting room area for labs and diagnostic imaging.
Study NCT04160234 — intervention group
Intervention type: OTHER
Intervention: web-based questionnaires
Description: Patients will be asked to complete web-based questionnaires on a tablet computer
Study NCT02046590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Study NCT02046590 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Study NCT01262222 — intervention group
Intervention type: OTHER
Intervention: endothelial function testing
Description: After obtaining informed consent, eligible patients will undergo endothelial function testing using the Endo-PAT 2000 (Itamar Medical) device. This PAT device applied to the finger tip will be used to measure change in blood flow in one arm at rest and after a 5 minute occlusion of the brachial artery with a blood pressure cuff. The other arm will serve as the patient's own control. After the cuff is deflated, blood flow normally increases in the arm for a period of time (flow mediated dilatation). In patients with abnormal endothelial function, this increase in blood flow is damped. The ratio of flow in the ischemic finger to the nonischemic finger (RH-PAT) will then be correlated with postoperative cardiac events.
Study NCT01435304 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: method of returning residual CPB blood ( Hemobag®)
Description: The Hemobag® is a collection reservoir used to facilitate ultrafiltration of the CPB circuit after the patient has been disconnected from CPB).
Study NCT02992236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VAS203
Description: Infusion of NO-Synthase inhibitor VAS203
Study NCT02992236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Infusion of saline
Study NCT00984893 — intervention group
Intervention type: DRUG
Intervention: zoledronic acid
Study NCT00984893 — intervention group
Intervention type: DRUG
Intervention: Any oral bisphosphonates marketed in Canada
Study NCT03596112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: application of a polyacrylate wound pad
Description: A sterile polyacrylate wound pad with activated carbon cloth treatment will be applied to chronic wounds in an outpatient clinic from a specialist nurse
Study NCT03596112 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocellular foam
Description: Active Comparator: hydrocellular foam pad serile hydrocellular standard foam pad will be applied to chronic wounds in an outpatient clinic from a specialist nurse
Study NCT02861222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Study NCT01385969 — intervention group
Intervention type: DEVICE
Intervention: Standard inflation of LMA cuff
Description: LMA cuff will be inflated per standard practice with a syringe and resulting cuff pressure will be measured by manual palpation of the cuff per standard practice.
Study NCT01385969 — intervention group
Intervention type: DEVICE
Intervention: Pressure check with syringe recoil
Description: LMA cuff will be inflated per standard practice with a syringe and resulting cuff pressure will be measured by syringe recoil
Study NCT01385969 — intervention group
Intervention type: DEVICE
Intervention: Pressure check by pressure transducer
Description: LMA cuff will be inflated per standard practice with a syringe and resulting cuff pressure will be measured by pressure transducer.
Study NCT06753630 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Extensor Muscle Strengthening Exercise
Description: A series of exercises aimed at strengthening the extensor muscles of the forearm to alleviate symptoms of lateral epicondylitis.
Study NCT03346772 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Description: Adults will receive one intramuscular dose of seasonal quadrivalent inactivated influenza vaccine, as indicated for standard of care.
Study NCT01091506 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once a day for 12 weeks
Study NCT01091506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L-methylfolate
Description: L-methylfolate 15mg once a day for 12 weeks
Study NCT03095144 — intervention group
Intervention type: DEVICE
Intervention: Spinal anesthesia
Description: Pyloromyotomy under spinal anesthesia
Study NCT03095144 — intervention group
Intervention type: DEVICE
Intervention: General anesthesia
Description: Pyloromyotomy under general anesthesia
Study NCT03258918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diabetes Prevention Program
Description: LC-DPP participants will be instructed to follow ad-libitum very low-carbohydrate, ketogenic diet, which restricts carbohydrate intake (not including fiber) to 20-35 grams per day with the goal of achieving nutritional ketosis. Participants will be encouraged to eat a normal amount of protein (roughly 80-120 grams per day) and to derive the remaining calories from fat. Allowable foods include: meats, fish, poultry, eggs, cheese, seeds, nuts, leafy greens, non-starchy vegetables, and some fruits.
Study NCT02718833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Study NCT02718833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Study NCT02718833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Study NCT02718833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT00806273 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vista Ultrasonic Bleach Bypass System
Description: The ultrasonic needle will be activated by depressing the foot pedal which will begin the debridement process. Irrigants will be delivered constantly at the recommended rate via the syringe pump and the needle tip will be moved up and down with a 2mm amplitude for the entire 1 minute activation cycle, which will deliver a total of 3ml of irrigant. The ultrasonic unit will be turned off and the needle will be withdrawn from the canal.
Study NCT00806273 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Needle Irrigation
Description: irrigation with 3ml 6% NaOCl is performed moving the needle from just short of binding to 2mm coronal in constant motion for 60 seconds and left untouched in a full canal for 60 seconds.
Study NCT04630691 — intervention group
Intervention type: PROCEDURE
Intervention: Implantation
Description: Patients received narrow diameter implants in posterior mandible or maxilla
Study NCT05202067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pharmaceutical education
Description: The patients who were assigned to the intervention group will receive a didactic talk from the research pharmacist. In addition, the patient will be given an updated list of their prescribed medications on a wallet card.
Study NCT03378674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil Injectable Product
Description: remifentanil: 0,15 mcg/kg/min
Study NCT03378674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil Injectable Product
Description: remifentanil: 0,15 mcg/kg/min
Study NCT01163851 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4 mg/kg
Description: RN316 10 mg/ml vial sd. Infusion based on weight Infusion duration = 60 minutes.
Study NCT01163851 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg
Description: RN316 10 mg/ml vial sd. Infusion based on weight Infusion duration = 60 minutes.
Study NCT02705300 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Irinotecan 165 mg/m2 iv
Description: Max. 4 months
Study NCT02705300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan 165 mg/m2 iv
Description: Max. 4 months
Study NCT02705300 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin 85 mg/m2 iv
Description: Max. 4 months
Study NCT02705300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 85 mg/m2 iv
Description: Max. 4 months
Study NCT02705300 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium folinate 200 mg/m2 iv
Description: Max. 6 months
Study NCT02705300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium folinate 200 mg/m2 iv
Description: Max. 6 months
Study NCT02705300 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-fluorouracil 3200 mg/m2
Description: Max. 6 months
Study NCT02705300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil 3200 mg/m2
Description: Max. 6 months
Study NCT02705300 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tocotrienol
Description: Max. 2 years or at the discretion of the investigator
Study NCT06753630 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extensor Muscle Strengthening Exercise
Description: A series of exercises aimed at strengthening the extensor muscles of the forearm to alleviate symptoms of lateral epicondylitis.
Study NCT02705300 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Max. 2 years or at the discretion of the investigator
Study NCT06753630 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Extracorporeal Shockwave Therapy
Description: A non-invasive procedure that uses shockwaves to promote healing and reduce pain in the affected area.
Study NCT06753630 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy
Description: A non-invasive procedure that uses shockwaves to promote healing and reduce pain in the affected area.
Study NCT06753630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection (Octreotide LAR placebo)
Description: A 3mL injection of saline solution used as a placebo in the study.
Study NCT06753630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polydeoxyribonucleotide Injection
Description: A 3mL injection of polydeoxyribonucleotide (5.625mg/3mL) used to enhance the healing process and improve outcomes in lateral epicondylitis treatment.
Study NCT00321698 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy (IMRT)
Description: Group 1=radiation only; All men in all Arms/Groups receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)
Study NCT00321698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel+IMRT
Description: Group 2=IV over 30mins, 10mg/m2; weekly x 5 weeks starting on day one of radiation; Group 3=IV over 30mins, 20mg/m2; weekly x 5 weeks starting on day one of radiation; Group 4=IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation; Phase II with no phase I dose-limiting toxicities=IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation~Radiation: All men receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)
Study NCT02173002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myIBDcoach
Study NCT02173002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Study NCT00534781 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: plasma microdebrider
Description: Coblation of the Achilles
Study NCT00534781 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Surgical Debridement
Description: Surgical Debridement of the Achilles
Study NCT03713060 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Mixed meal test
Description: All women will have mixed meal test, continous glucose monitoring and antenatal ultrasounds performed. The children born of these women will have DXA-scans performed after birth.
Study NCT02983188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Berberine
Description: Berberine tablets, 0.3g every time, two times daily
Study NCT02983188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo tablets, 0.3g every time, two times daily
Study NCT02983188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antipsychotic Agents
Description: Antipsychotic agents prescribed at the discretion of the patients' psychiatrists with respect to patients' conditions. Concomitant use of other psychotropic drugs, including antidepressants, anxiolytics, and mood stabilizers for mood disorders, benzodiazepines and non-benzodiazepines for insomnia, and anticholinergics for extrapyramidal symptoms, was allowed as usual. For those who were under anti-hyperlipidemic, antihypertensive and anti-diabetic treatment, they were allowed to continue their current medications throughout the study.
Study NCT02983188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antipsychotic Agents
Description: Antipsychotic agents prescribed at the discretion of the patients' psychiatrists with respect to patients' conditions. Concomitant use of other psychotropic drugs, including antidepressants, anxiolytics, and mood stabilizers for mood disorders, benzodiazepines and non-benzodiazepines for insomnia, and anticholinergics for extrapyramidal symptoms, was allowed as usual. For those who were under anti-hyperlipidemic, antihypertensive and anti-diabetic treatment, they were allowed to continue their current medications throughout the study.
Study NCT04065984 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Microstim 2v2 Stimulator
Description: Neuro-muscular electrical stimulator portable device (9v battery) connected to the skin participant over the muscle body of choice using self adhesive electro-gel pads. Treatment devices and placebo devices.
Study NCT04065984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microstim 2v2 Stimulator
Description: Neuro-muscular electrical stimulator portable device (9v battery) connected to the skin participant over the muscle body of choice using self adhesive electro-gel pads. Treatment devices and placebo devices.
Study NCT00002924 — intervention group
Intervention type: OTHER
Intervention: mutation analysis
Study NCT03466463 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GNT0003
Description: Intravenous infusion, single dose
Study NCT02416609 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: LDR
Description: LDR will be delivered during each cycle of Gem-based doublets
Study NCT02416609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gem-based doublets
Description: 4 cycles of Gem-based doublets
Study NCT02416609 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT will be administered after the fourth Gem-based doblet cycle, if no progression; three fractions will be administered
Study NCT01488383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Purified extract of Rebaudina Stevia-Stevioside
Description: volunteers will take only one capsule of stevioside (one day), and then corresponding measurements will be performed.
Study NCT01488383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium saccharin
Description: Volunteers will take one capsule of saccharin 250mg (one day) and then, corresponding measurements will be performed
Study NCT00820053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin and lipiodol
Description: using the technology of Seldinger,The drugs (30 mg epirubicin mixed with 5 ml lipiodol) are given via hepatica propria artery.
Study NCT01158846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prasugrel/bivalirudin
Description: 60mg loading dose followed by 10mg or 5 mg (according to body weight or age)maintenance dose of prasugrel. Bivalirudin during the primary PCI (bolus plus infusion)
Study NCT01158846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel/abciximab
Description: 600mg loading dose of clopidogrel followed by 75mg maintenance dose. Abciximab will be used during primary PCI, bolus plus infusion.
Study NCT04754828 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assigned to a rounding style
Description: Team rounded on new admissions either in hallway or at the bedside
Study NCT04468347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: IV injection, 240 megabecquerel (MBq) (6.5 mCi)
Study NCT04468347 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain PET scan
Description: positron emission tomography (PET) scan of the brain
Study NCT02713932 — intervention group
Intervention type: DEVICE
Intervention: Transcatheter aortic valve implantation